Cargando…
Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature
BACKGROUND: Adjuvant chemotherapy (AC) is recommended since 2004 for patients with a completely resected non-small cell lung cancer (NSCLC). Indeed, several randomized clinical trials have demonstrated an improved survival for patients treated with adjuvant cisplatin-based regimen than surgery alone...
Autores principales: | Desage, Anne-Laure, Bouleftour, Wafa, Tiffet, Olivier, Fournel, Pierre, Tissot, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743521/ https://www.ncbi.nlm.nih.gov/pubmed/35070767 http://dx.doi.org/10.21037/tlcr-21-557 |
Ejemplares similares
-
Adjuvant chemotherapy for completely resected IIA–IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice
por: Désage, Anne-Laure, et al.
Publicado: (2022) -
Spread Through Air Spaces (STAS) Is an Independent Prognostic Factor in Resected Lung Squamous Cell Carcinoma
por: Dagher, Sami, et al.
Publicado: (2022) -
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis
por: Yvorel, Violaine, et al.
Publicado: (2017) -
Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report
por: Hean, Virginie, et al.
Publicado: (2021) -
Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas
por: Karpathiou, Georgia, et al.
Publicado: (2022)